JCXH-108
/ Immorna
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 01, 2025
JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
(clinicaltrials.gov)
- P1 | N=75 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Trial completion date: Mar 2025 ➔ Jun 2025 | Trial primary completion date: Mar 2025 ➔ Jun 2025
Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
March 20, 2025
JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
(clinicaltrials.gov)
- P1 | N=75 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
September 26, 2024
JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an MRNA-based Vaccine Against RSV
(clinicaltrials.gov)
- P1 | N=75 | Recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
August 21, 2024
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
(clinicaltrials.gov)
- P1 | N=75 | Not yet recruiting | Sponsor: Immorna Biotherapeutics, Inc.
New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 4
Of
4
Go to page
1